The Supreme Court granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a dispute over whether a generic manufacturer's off-label marketing can give rise to induced infringement liability when the FDA label fully carves out the patented indication.
